Should I buy Cencora (COR) stock or is it too late?

Cencora · Health Care · price $321

⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: Morgan Stanley — 69% of its targets hit on this sector (825 calls tested). It aims for $346 (+7.7 %), call made on August 8, 2026, maturing on August 8, 2027 (20 d ago).

The 6 reliable analysts $370+15 %

The 4 other firms $345+7.2 %

How to read it: the 6 reliable firms are not filtered by optimism — 5 aim above the price, 1 below, hence their $370 median. “The 4 others” are the firms that don't pass our reliability filter on this sector.

Firm-by-firm track record on Cencora

Here the hit rate is measured <b>on this stock specifically</b> (matured targets replayed against real prices, minimum 5 calls tested) — the green block above measures reliability <b>across the whole sector</b>, which is the criterion behind JPI selections. “Aims for” = the firm's most recent target on this stock; “—” means it hasn't published one recently.

Firm	% right	Gain vs sector	Calls	Aims for
Baird	80 %	+24.3 %	5	$339 +6%

In short — Should you invest in Cencora? Is it too late, still worth it? Analysts are fairly positive (73% buy, median target $350, i.e. +9%), and the most reliable on COR targets even higher. We give you both sides, with the numbers — not advice.

✅ Reasons to believe

73% of analysts rate it a buy (Buy consensus, 11 ratings) — a sign of market conviction.
Median price target $350, i.e. +9% from the current price ($321).
The most reliable firm on COR, Evercore ISI Group (100% hit rate, 2 scored calls), targets $350 (call made on August 6, 2026, maturing on August 6, 2027) (+9%) in its most recent call, and $420 (call made on February 5, 2026, maturing on February 5, 2027) (+31%) in the one coming due soonest.
5 analysts rated reliable (≥55% hit rate, beat their sector) are bullish on the stock.

⚠️ Reasons to hesitate

The consensus is not unanimous: of 11 ratings, 3 are neutral.
A 12-month target is not a guaranteed path: the price can fall in the meantime.

The analyst consensus on COR

Median target $350 (+9%) · 11 ratings · Buy consensus

Strong Buy00%

Buy873%

Hold327%

Sell00%

Strong Sell00%

⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.

Frequently asked questions

Should you invest in Cencora now?

We won't decide for you. The facts: 73% of analysts rate it a buy, median target $350 (+9%), and Evercore ISI Group (most reliable on COR, 100%) targets $350. Weigh that against valuation (P/E ~24). This is not personalized advice.

Is it too late to invest in Cencora?

Not according to analysts: the median target ($350) is still +9% above the current price ($321) (most reliable on COR: Evercore ISI Group, 100%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.

Is Cencora still worth investing in?

It depends on the gap between the price ($321) and its estimated value: analysts target $350 on median (+9%), with 73% buys (most reliable on COR: Evercore ISI Group, 100%). Cross-check with their real reliability on COR and the cautions above. Information, not advice.

What's the main risk in buying COR?

The consensus is not unanimous: of 11 ratings, 3 are neutral.

→ Go deeper: the full Cencora profile (consensus, analyst reliability, price target, performance).